I004 (insulin aspart rapid-acting biosimilar)
/ Amphastar
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 20, 2023
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
(clinicaltrials.gov)
- P2/3 | N=69 | Completed | Sponsor: Amphastar Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Jan 2023
Trial completion • Trial completion date
September 14, 2022
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
(clinicaltrials.gov)
- P2/3 | N=60 | Recruiting | Sponsor: Amphastar Pharmaceuticals, Inc.
New P2/3 trial
1 to 2
Of
2
Go to page
1